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To the Editor: We read with much interest the mini review
‘Treatment of immunoglobulin A nephropathy’ by Barrat
and Feehally,1 and were very pleased to note that, after many
debates between us at many meetings, Dr Feehally finally
accepts the results of our trial2,3 strongly suggesting the use of
steroids in patients with immunoglobulin A nephropathy
and persistent proteinuria (41 g/24 h), after aiming at a
blood pressure target value of 125/75 mmHg using anti-
hypertensive drugs, including angiotensin-converting enzyme
inhibitors and angiotensin II receptor blockers at maximum
doses and, if necessary, in combination. However, this
agreement clearly contradicts what is said in Table 1, which
contain no recommendation concerning the use of steroids in
patients with proteinuria levels of 41 g/24 h.
It is surprising that the abstract makes no mention of the
use of steroids for patients with proteinuria levels of 41 g/
24 h and refers to no evidence in favor of using steroids for
nephrotic immunoglobulin A nephropathy beyond the group
of minimal change nephropathy, whereas the text states that
‘the risk attributable to proteinuria is almost certainly a
continuum’. We agree that there is no evidence proving the
efficacy of steroids in this patient population, but no evidence
does not mean they should not be used, but just that there are
no randomized studies supporting their use. Nihilism while
awaiting the publication of randomized trials (which, to the
best of our knowledge, are not even planned) could be very
dangerous for the patients because, as the authors say
themselves, heavy proteinuria is also the most important factor
of progression in patients with immunoglobulin A nephropathy.
1. Barratt J, Feehally J. Treatment of IgA nephropathy. Kidney Int 2006; 69:
1934–1938.
2. Pozzi C, Bolasco PG, Fogazzi GB et al. Corticosteroids in IgA nephropathy:
a randomised controlled trial. Lancet 1999; 353: 883–887.
3. Pozzi C, Andrulli S, Del Vecchio L et al. Corticosteroid effectiveness in IgA
nephropathy: long-term results of a randomized, controlled trial. J Am Soc
Nephrol 2004; 15: 157–163.
F Locatelli1, S Andrulli1 and C Pozzi1
1A. Manzoni Hospital, Nephrology and Dialysis, Lecco, Italy
Correspondence: F Locatelli, A Manzoni Hospital, Nephrology and Dialysis,
Lecco, Italy. E-mail: f.locatelli@ospedale.lecco.it
Response to ‘Steroids and IgA
nephritis’
Kidney International (2006) 70, 1661–1662. doi:10.1038/sj.ki.5001857
We appreciate the interest of Dr Locatelli et al.1 in our
discussion of the treatment of IgA nephropathy.
It is not surprising, given the relative lack of robust
evidence, that there is a range of opinions about the
preferred treatment approaches to patients with IgA
nephropathy at risk for progressive renal failure, and Dr
Locatelli et al. have not interpreted our article as we had
intended.
We are in agreement that there is evidence that
increasing proteinuria marks a continuum of risk; how-
ever, the threshold of proteinuria 41 g/24 h was an entry
criteria for a number of treatment trials in IgA nephro-
pathy (including the trial of corticosteroids by our
correspondents). It might be appropriate to extend the
use of treatments effective for proteinuria 41 g/24 h to
patients with lesser degrees of proteinuria provided that
such treatments are well tolerated with very low toxicity.
The dosing regimen for corticosteroids studied by our
correspondents is substantial – over 6 months they gave 9 g
intravenous methylprednisolone with oral prednisolone
0.5 mg/kg/day. Although in their published study they state
this regimen was well tolerated by their patients and with
few adverse effects, in our experience such a regimen has
considerable short and longer term toxicity, which
strengthens our reluctance to recommend it in circum-
stances where its benefits have not been subject to
randomized controlled trial.
The crucial question is whether corticosteroids or other
immunosuppressive regimens give added benefit when
patients are treated to contemporary blood pressure goals
(125/75), with adequate blockade of the renin–angiotensin
system, using combination therapy with angiotensin
converting enzyme inhibitors and angiotensin receptor
blockers. In our opinion, the answer to this question is
uncertain since many of the studies we review in our
article, including that of Dr Locatelli et al., do not have
such contemporary best practice in the control limb of the
randomization. The analysis we provided in our article
emphasizes the need for caution since those few interven-
tion studies reporting rigorous blood pressure control with
effective renin–angiotensin blockade are in general those
least likely to show benefit for an additional treatment.
Our observations are not intended to criticize the
investigators who undertook these studies, since most were
designed and initiated when such standards of care for
blood pressure control and renin–angiotensin blockade
were not recognized; indeed, their contribution is much to
be respected when so few investigators around the world
have completed treatment trials in this common glomer-
ular disease.
As we recognize that corticosteroids remains the choice
of many nephrologists, we mentioned in the text of our
article that their use should be ‘considered’ but only in
circumstances where their use might be considered most
logical – if a patient still meets the entry criteria of the trial
of Dr Locatelli et al. (proteinuria 41 g/24 h) despite
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optimal management of blood pressure and full renin–an-
giotensin blockade. But since we are not satisfied their
benefit is proven even in that setting, we do not include
corticosteroids in our main treatment recommendations in
the table or abstract of our article. What Dr Locatelli et al.
regard as ‘nihilism’, we regard as pragmatic realism
avoiding a treatment regimen with some toxicity when
evidence in favor of its use is insecure.
Unfortunately, these uncertainties will not easily be
resolved. Modern management with adequate blood
pressure control and renin–angiotensin blockade is redu-
cing proteinuria and slowing the progression of a
significant proportion of patients with IgA nephropathy.
Proof that treatments additional to this regimen are
effective will therefore require larger and more prolonged
treatment trials unless surrogate markers of progression
become more discriminatory, and our ability to define risk
of progression in individual patients becomes more
refined.
1. Locatelli et al. Steroids and IgA nephritis. Kidney Int 2006, in press.
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To the Editor: Gerntholtz et al.1 report their series of kidney
biopsies from Black African human immunodeficiency virus
(HIV)-positive patients, adding to a growing literature
suggesting HIV-associated nephropathy (HIVAN) to be less
common than originally described.2,3 They found HIV
immune complex kidney disease to be as common as
HIVAN, and describe for the first time a ‘ball-in-cup’
appearance on silver-methenamine staining or electron
microscopy caused by subepithelial deposits associated with
basement membrane reaction, placing this lesion as an
intermediate between classical post-infectious and membra-
nous glomerulonephritis.
On review of 10 Black African HIV-positive patients
biopsied in East London after July 2004, we found a similar
prevalence of HIVAN (3/10) and immune complex-mediated
glomerulonephritis with mesangial matrix increase and
crescent formation (3/10). The ‘ball-in-cup’ lesion newly
described as typical of HIV immune complex kidney disease was
apparent in only one of the three such cases on re-examining
renal tissue. Our patients were similar in age (30–45 years),
renal function (creatinine 4627620 mmol/l, mean7s.d.),
serum albumin (2879 g/l), and CD4 count (2107155 co-
pies/ml). HIV viral load was 4.2870.88 106/l, and none
were intravenous drug users or hepatitis B positive.
Unlike the Gerntholtz series in which of those known to
follow-up 58% died, the outcome was generally good (with
universally good response to anti-retroviral drugs). Despite
often advanced presentation, only one patient has died to
date after a mean 46 weeks follow-up, and of two patients
requiring hemodialysis (both with HIVAN), one has since
recovered independent renal function. In Black African
migrants living in London, similar rates of HIVAN and
immune complex-mediated kidney disease are seen to that
described in Johannesburg – the renal and patient outcome is
however very different, emphasizing the importance of
readily available anti-retroviral therapy.
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The kidney biopsy experience of Cove-Smith et al.1 in an
East London setting with Black African human immuno-
deficiency virus (HIV)-positive patients is interesting in its
parallels to ours. We feel that this emphasizes the fact that
not all that is kidney disease in the context of HIV
infection is classic HIV-associated nephropathy. There are
many other forms of renal pathology which occur, empha-
sizing the need for renal biopsy to allow full clarification.
Although detailed histopathological clarification does
not carry proven therapeutic implications at this stage, we
are at present treating all those with HIV-associated
nephropathy and HIV immune complex kidney disease
with angiotensin-converting enzyme inhibitors and anti-
retroviral therapy, regardless of the CD4 count, as we feel
that the virus is involved in the pathophysiology. This
contrasts with our published experience,2 when antiretro-
viral therapies were not used as they were not available to
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